Search for Clinical Trial Results

Sponsored By

Hemophilia A - 30 Studies Found

Status Study
Recruiting Study Name: Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Condition: Acquired Hemophilia A
Date: 2015-10-29
Interventions: Biological: OBIZUR Treating physician will determine treatment regimen, frequency of laboratory and clin
No longer available Study Name: Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies
Condition: Acquired Hemophilia A
Date: 2013-10-21
Interventions: Biological: OBI-1 Other Name: B-Domain Deleted Recombinant Porcine Factor VIII
Terminated Study Name: Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A
Condition: Hemophilia A
Date: 2006-03-23
Interventions:
  • Drug: Rituxan Acquired Hemophi
Completed Study Name: Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A
Condition: Hemophilia A
Date: 2010-08-06
Interventions: Biological: OBI-1 Intravenous infusion
Completed Study Name: Inhibitor Development in Patients With Hemophilia A Undergoing Surgery
Condition: Hemophilia A
Date: 2012-04-04
Completed Study Name: Study of a pd vWF/FVIII, Biostate®, in Subjects With Haemophilia A
Condition: Hemophilia A
Date: 2009-04-09
Interventions:
  • Biological: Biostate® [SP]

Completed Study Name: Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery
Condition: Hemophilia A
Date: 2004-09-28
Interventions: Drug: ReFacto
Completed Study Name: Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A
Condition: Hemophilia A
Date: 2005-09-11
Interventions:
  • Drug: ReFacto
  • Drug: Advante
Completed Study Name: Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients
Condition: Hemophilia A
Date: 2009-06-04
Interventions:
  • Biological: Moroctocog alfa ( AF-CC)

Recruiting Study Name: Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A
Condition: Haemophilia A
Date: 2013-03-13
Interventions: Biological: Optivate 500IU
Next >>>